{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:14:51Z","timestamp":1786994091227,"version":"build-2736575974"},"reference-count":14,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.medj.2025.100927","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T21:23:13Z","timestamp":1763155393000},"page":"100927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Metastatic prostate cancer: Clinical trials to watch"],"prefix":"10.1016","volume":"6","author":[{"given":"Georges","family":"Gebrael","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah","family":"Ostrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2025.100927_bib1","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate Cancer: A Review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2025.100927_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2025.03.019","article-title":"Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis","author":"Miszczyk","year":"2025","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.medj.2025.100927_bib3","article-title":"Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design","volume":"42","author":"Azad","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100927_bib4","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS232","article-title":"EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-na\u00efve prostate cancer in the era of new AR pathway inhibitors","volume":"42","author":"Grisay","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100927_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5129","article-title":"TRIPLE-SWITCH (SWOG\/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924)","volume":"43","author":"Ong","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100927_bib6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","article-title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Agarwal","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2025.100927_bib7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2217\/fon-2023-0526","article-title":"TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer","volume":"20","author":"Agarwal","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.medj.2025.100927_bib8","doi-asserted-by":"crossref","first-page":"TPS5123","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5123","volume":"42","author":"Chi","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100927_bib9","article-title":"Mevrometostat (PF-06821497) in combination with enzalutamide for androgen receptor pathway inhibitor (ARPI)-na\u00efve patients with metastatic castration-resistant prostate cancer (mCRPC): The phase 3, randomized MEVPRO-2 trial","volume":"43","author":"Schweizer","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100927_bib10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.medj.2025.100927_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5118","article-title":"Trial in progress (XALute): Phase 3 study of xaluritamig vs investigator\u2019s choice of cabazitaxel or second androgen receptor directed therapy (ARDT) in post-taxane metastatic castration-resistant prostate cancer (mCRPC)","volume":"43","author":"Kelly","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100927_bib12","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1200\/JCO-25-00678","article-title":"Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study","volume":"43","author":"Stein","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100927_bib13","article-title":"Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer","volume":"3","author":"Fizazi","year":"2024","journal-title":"NEJM Evid."},{"key":"10.1016\/j.medj.2025.100927_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS301","article-title":"Phase 3 OMAHA-004 study of CYP11A1 inhibitor opevesostat versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after 1 prior NHA","volume":"43","author":"Gratzke","year":"2025","journal-title":"J. Clin. Oncol."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663402500354X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663402500354X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:43:28Z","timestamp":1773409408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663402500354X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S266663402500354X"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2025.100927","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metastatic prostate cancer: Clinical trials to watch","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2025.100927","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100927"}}